A detailed history of Qube Research & Technologies LTD transactions in Gossamer Bio, Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 181,638 shares of GOSS stock, worth $174,372. This represents 0.0% of its overall portfolio holdings.

Number of Shares
181,638
Previous 659,685 72.47%
Holding current value
$174,372
Previous $778,000 79.05%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$0.51 - $1.27 $243,803 - $607,119
-478,047 Reduced 72.47%
181,638 $163,000
Q1 2024

May 14, 2024

BUY
$0.8 - $1.51 $344,874 - $650,950
431,093 Added 188.59%
659,685 $778,000
Q4 2023

Feb 13, 2024

BUY
$0.48 - $1.08 $109,724 - $246,879
228,592 New
228,592 $208,000
Q2 2023

Aug 14, 2023

SELL
$0.98 - $1.53 $112,726 - $175,991
-115,027 Reduced 57.58%
84,744 $101,000
Q1 2023

May 15, 2023

BUY
$0.96 - $2.92 $191,780 - $583,331
199,771 New
199,771 $251,000
Q3 2022

Nov 14, 2022

BUY
$7.21 - $14.88 $827,506 - $1.71 Million
114,772 New
114,772 $1.38 Million
Q2 2022

Aug 15, 2022

SELL
$5.97 - $9.97 $400,604 - $669,016
-67,103 Closed
0 $0
Q1 2022

May 09, 2022

BUY
$8.44 - $12.49 $566,349 - $838,116
67,103 New
67,103 $582,000
Q3 2021

Nov 12, 2021

SELL
$7.25 - $13.23 $96,214 - $175,575
-13,271 Closed
0 $0
Q2 2021

Aug 13, 2021

BUY
$8.0 - $9.75 $106,168 - $129,392
13,271 New
13,271 $108,000
Q3 2020

Nov 12, 2020

SELL
$11.3 - $14.75 $302,941 - $395,432
-26,809 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$9.52 - $15.98 $255,221 - $428,407
26,809 New
26,809 $349,000

Others Institutions Holding GOSS

About Gossamer Bio, Inc.


  • Ticker GOSS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 93,954,000
  • Market Cap $90.2M
  • Description
  • Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony...
More about GOSS
Track This Portfolio

Track Qube Research & Technologies LTD Portfolio

Follow Qube Research & Technologies LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

News

Stay updated on Qube Research & Technologies LTD with notifications on news.